ArticleProtein & cell2015
MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma.
Article in Protein & cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- A Dually Nanobody-Engineered Milk-Derived Extracellular Vesicle Nanomedicine Targeting Tumour-Associated Macrophages and Cancer Cells for Cancer Therapy.Journal of extracellular vesicles · 2026Article
- Phospholipase D: emerging therapeutic targets in signaling, metabolism, and immune-oncology.Cell communication and signaling : CCS · 2025Review
- 17β-Estradiol Abrogates TNF-α-Induced Human Brain Vascular Pericyte Migration by Downregulating miR-638 via ER-β.International journal of molecular sciences · 2024Article
- Circular RNA SNX27 Facilitates Gastric Cancer Progression By Sponging miR-638.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- miR-638 suppresses cervical cancer progression by inhibitingHistology and histopathology · 2024Article
- ELOA promotes tumor growth and metastasis by activating RBP1 in gastric cancer.Cancer medicine · 2023Article
- Methylation‑associated silencing of miR‑638 promotes endometrial carcinoma progression by targeting MEF2C.International journal of molecular medicine · 2020Article
- miR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma.American journal of translational research · 2020Article
- Phospholipase D1 Ameliorates Apoptosis in Chronic Renal Toxicity Caused by Low-Dose Cadmium Exposure.BioMed research international · 2020Article
- MicroRNA-638 inhibits human aortic valve interstitial cell calcification by targeting Sp7.Journal of cellular and molecular medicine · 2019Article
- A mathematical model as a tool to identify microRNAs with highest impact on transcriptome changes.BMC genomics · 2019Article
- Emerging roles of circRNA in formation and progression of cancer.Journal of Cancer · 2019Review
- MiR-638 Repressed Vascular Smooth Muscle Cell Glycolysis by Targeting LDHA.Open medicine (Warsaw, Poland) · 2019Article
- Down-regulation of circPVRL3 promotes the proliferation and migration of gastric cancer cells.Scientific reports · 2018Article
- Expression of microRNA 638 and sex-determining region Y-box 2 in hepatocellular carcinoma: Association between clinicopathological features and prognosis.Oncology letters · 2018Article
- How miRs and mRNA deadenylases could post-transcriptionally regulate expression of tumor-promoting protein PLD.Advances in biological regulation · 2018Review
- MiR-638 acts as a tumor suppressor gene in gastric cancer.Oncotarget · 2017Article
- Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients.Oncotarget · 2017Article
- MicroRNA expression in bone marrow-derived human multipotent Stromal cells.BMC genomics · 2017Article
- MeCP2, a target of miR-638, facilitates gastric cancer cell proliferation through activation of the MEK1/2-ERK1/2 signaling pathway by upregulating GIT1.Oncogenesis · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are a type of small non-coding RNAs that are often play important roles in carcinogenesis, but the carcinogenic mechanism of miRNAs is still unclear. This study will investigate the function and the mechanism of miR-638 in carcinoma (GC). The expression of miR-638 in GC and the DNA copy number of miR-638 were detected by real-time PCR. The effect of miR-638 on cell proliferation was measured by counting kit-8 assay. Different assays, including bioinformatics algorithms (TargetScan and miRanda), luciferase report assay and Western blotting, were used to identify the target gene of miR-638 in GC. The expression of miR-638 target gene in clinical CRC tissues was also validated by immunohistochemical assay. From this research, we found that miR-638 was downregulated in GC tissues compared with corresponding noncancerous tissues (NCTs), and the DNA copy number of miR-638 was lower in GC than NCTs, which may induce the corresponding downregulation of miR-638 in GC. Ectopic expression of miR-638 inhibited GC cell growth in vitro. Subsequently, we identified that PLD1 is the target gene of miR-638 in GC, and silencing PLD1 expression phenocopied the inhibitory effect of miR-638 on GC cell proliferation. Furthermore, we observed that PLD1 was overexpressed in GC tissues, and high expression of PLD1 in GC predicted poor overall survival. In summary, we revealed that miR-638 functions as a tumor suppressor in GC through inhibiting PLD1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.